Straits Times Index
3,306.13 -15.95 (-0.48%) Nikkei
39,134.79 +96.63 (+0.25%) Hang Seng
18,194.52 -172.43 (-0.94%) FTSE 100
8,230.50 +2.02 (+0.02%) Bitcoin USD
67,355.33 -2,040.38 (-2.94%) CMC Crypto 200
1,398.92 -42.72 (-2.96%)
TEVA Jun 2024 14.000 call
| Previous close | 3.0500 |
| Open | 3.0500 |
| Bid | 2.3800 |
| Ask | 3.5000 |
| Strike | 14.00 |
| Expiry date | 2024-06-07 |
| Day's range | 3.0500 - 3.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 42 |
Business WireTeva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
TEL AVIV, Israel, June 04, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time.
ZacksTEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia
